Registry of MRI guided transurethral ultrasound ablation
Research type
Research Study
Full title
Registry study for MRI-Guided Transurethral Ultrasound Ablation (TULSA) of organ confined prostate cancer.
IRAS ID
245239
Contact name
Steven Bandula
Contact email
Sponsor organisation
Profound Medical Corporation
Duration of Study in the UK
30 years, 0 months, 1 days
Research summary
Prostate cancer is the most prevalent cancer among men and is one of the principal medical problems facing the male population. While conventional radical treatments for localised prostate cancer such as surgery or radiotherapy provide good local control of disease, they leave men with significant long term complications affecting urinary, bowel and sexual function which can reduce the patient's quality of life. New treatments are now able to treat only the cancer and not the entire prostate, theoretically lowering the risk of complications. One such treatment uses ultrasound waves emitted from a probe placed in a patient's urethra (tube in the penis where urine is expelled) to heat up the prostate where the cancer is. The treatment is performed with the patient in the magnetic resonance imaging (MRI) scanner which can be used to find, target and monitor the treatment. This treatment is being used to treat prostate cancer in a few countries and has started at University College London Hospital (UCLH) in London.
This study is a prospective, observational, non-inteventional study. Subjects will only be approached once they and the clinical team have both decided they are suitable for MR guided ultrasound ablation of their prostate cancer, independent of this study. This study will capture data from these treatments to study the safety profile and efficacy of the treatment in patients being treated.
REC name
London - Queen Square Research Ethics Committee
REC reference
19/LO/1533
Date of REC Opinion
27 Sep 2019
REC opinion
Favourable Opinion